Advocacy intelligence hub — real-time data for patient organizations
New York Medical College — PHASE2
University of Turin, Italy
Beijing Tsinghua Chang Gung Hospital
Duke University
Children's Mercy Hospital Kansas City — NA
Defitelio: FDA approved
For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Defitelio
(defibrotide)Orphan drugJazz Pharmaceuticals, Inc.
12.1 Mechanism of Action The mechanism of action of defibrotide sodium has not been fully elucidated. In vitro , defibrotide sodium enhances the enzym...
Selim Corbacioglu, MD
University of Ulm, Germany
Mitchell Cairo, MD, MD
New York Medical College
📍 HAWTHORNE, NY
Paul Richardson, MD
Dana-Farber Cancer Institute
Paul Richardson, M.D.
Dana-Farber Cancer Institute
John Horan, MD
Emory University
📍 Birmingham, Alabama
Kris Mahadeo, M.D
Duke University
📍 DURHAM, NC